Biocon likely to seek full marketing authorisation for Covid-19 drug

Expects results from phase 4 study of itolizumab by end of this quarter

Sohini Das Mumbai
biocon, pharma, research

If the DCGI gives nod, it will be the first drug to have full authorization for use in Covid patients

Bangalore-headquartered Biocon may consider applying for full marketing authorisation for itolizumab, a novel antibody product used to treat Covid-19 patients, in India. 
If the Drugs Controller General of India (DCGI) gives a nod for marketing authorization, itolizumab (brand name Alzumab) will become the first drug to have full authorization for use in Covid-19 patients. So far, repurposed drugs, such as Gilead’s remdesivir (an antiviral) or Roche’s tocilizumab (an antibody), have emergency use authorizations in different countries.
Arun Chandavarkar, managing director of the Bengaluru-headquartered company, said: “We expect results from the phase 4 study on itolizumab by the end of this quarter. This would be real-world data from around 300 patients.”

Also Read

Healing a weak regulator

Decision in 3 working days after foreign Covid-19 vaccine firms apply

Amid weak showing by biosimilars and generics, downgrade pressure on Biocon

Roche seeking fast approval of antibody cocktail in India to treat Covid

Cipla launches Roche's Covid antibody cocktail in India for Rs 60k per dose

Elon Musk wants to bring Tesla to India, blames high import duties on EVs

OPPO captures second spot in global smartphone market in May: Report

Domino's ties up with Revolt Motors to convert petrol bike fleet into EVs

'Zomato's stellar IPO to have positive impact on foodtech firms' valuation'

Majesco to acquire 51% stake in Pune-based K2V2 for Rs 40 crore


  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 5Y
  • MAX

First Published: Jul 26 2021 | 12:45 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on are available only to BS Premium subscribers. Already a BS Premium subscriber?LOGIN NOW

Register to